Cargando…
Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity?
ESSENTIALS: Platelet function defects may cause atypical bleeding symptoms in immune thrombocytopenia (ITP). An isolated platelet defect of collagen‐induced aggregation was explored in a patient with ITP. ITP mediated by antibodies to glycoprotein (GP) VI curtail receptor function. Inclusion of GPVI...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058269/ https://www.ncbi.nlm.nih.gov/pubmed/30046699 http://dx.doi.org/10.1002/rth2.12033 |
_version_ | 1783341661856727040 |
---|---|
author | Rabbolini, David J. Gardiner, Elizabeth E. Morel‐Kopp, Marie‐Christine Dunkley, Scott Jahangiri, Anila Lee, Christine S‐M. Stevenson, William S. Ward, Christopher M. |
author_facet | Rabbolini, David J. Gardiner, Elizabeth E. Morel‐Kopp, Marie‐Christine Dunkley, Scott Jahangiri, Anila Lee, Christine S‐M. Stevenson, William S. Ward, Christopher M. |
author_sort | Rabbolini, David J. |
collection | PubMed |
description | ESSENTIALS: Platelet function defects may cause atypical bleeding symptoms in immune thrombocytopenia (ITP). An isolated platelet defect of collagen‐induced aggregation was explored in a patient with ITP. ITP mediated by antibodies to glycoprotein (GP) VI curtail receptor function. Inclusion of GPVI in diagnostic antibody detection assays may improve their diagnostic utility. Idiopathic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by relapsing/ remitting thrombocytopenia. Bleeding complications are infrequent with platelet counts above 30×10(9)/L, and this level is commonly used as a threshold for treatment. The question of another/ co‐existent diagnosis or an alternate mechanism of platelet destruction arises when bleeding is experienced with platelet counts above this threshold. We report a case of anti‐GPVI mediated ITP that was diagnosed following investigations performed to address this key clinical question. A patient with ITP experienced exaggerated bruising symptoms despite a platelet count of 91×10(9)/L. Platelet functional testing showed an isolated platelet defect of collagen‐induced aggregation. Next generation sequencing excluded a pathogenic variant of GP6, and anti‐GPVI antibodies that curtailed GPVI function were confirmed by extended platelet phenotyping. We propose that anti‐GPVI mediated ITP may be under‐recognized, and that inclusion of GPVI in antibody detection assays may improve their diagnostic utility and in turn, facilitate a better understanding of ITP pathophysiology and aid individualized treatment approaches. |
format | Online Article Text |
id | pubmed-6058269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60582692018-07-25 Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? Rabbolini, David J. Gardiner, Elizabeth E. Morel‐Kopp, Marie‐Christine Dunkley, Scott Jahangiri, Anila Lee, Christine S‐M. Stevenson, William S. Ward, Christopher M. Res Pract Thromb Haemost Case Reports ESSENTIALS: Platelet function defects may cause atypical bleeding symptoms in immune thrombocytopenia (ITP). An isolated platelet defect of collagen‐induced aggregation was explored in a patient with ITP. ITP mediated by antibodies to glycoprotein (GP) VI curtail receptor function. Inclusion of GPVI in diagnostic antibody detection assays may improve their diagnostic utility. Idiopathic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by relapsing/ remitting thrombocytopenia. Bleeding complications are infrequent with platelet counts above 30×10(9)/L, and this level is commonly used as a threshold for treatment. The question of another/ co‐existent diagnosis or an alternate mechanism of platelet destruction arises when bleeding is experienced with platelet counts above this threshold. We report a case of anti‐GPVI mediated ITP that was diagnosed following investigations performed to address this key clinical question. A patient with ITP experienced exaggerated bruising symptoms despite a platelet count of 91×10(9)/L. Platelet functional testing showed an isolated platelet defect of collagen‐induced aggregation. Next generation sequencing excluded a pathogenic variant of GP6, and anti‐GPVI antibodies that curtailed GPVI function were confirmed by extended platelet phenotyping. We propose that anti‐GPVI mediated ITP may be under‐recognized, and that inclusion of GPVI in antibody detection assays may improve their diagnostic utility and in turn, facilitate a better understanding of ITP pathophysiology and aid individualized treatment approaches. John Wiley and Sons Inc. 2017-08-24 /pmc/articles/PMC6058269/ /pubmed/30046699 http://dx.doi.org/10.1002/rth2.12033 Text en © 2017 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Rabbolini, David J. Gardiner, Elizabeth E. Morel‐Kopp, Marie‐Christine Dunkley, Scott Jahangiri, Anila Lee, Christine S‐M. Stevenson, William S. Ward, Christopher M. Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title | Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title_full | Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title_fullStr | Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title_full_unstemmed | Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title_short | Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity? |
title_sort | anti‐glycoprotein vi mediated immune thrombocytopenia: an under‐recognized and significant entity? |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058269/ https://www.ncbi.nlm.nih.gov/pubmed/30046699 http://dx.doi.org/10.1002/rth2.12033 |
work_keys_str_mv | AT rabbolinidavidj antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT gardinerelizabethe antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT morelkoppmariechristine antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT dunkleyscott antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT jahangirianila antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT leechristinesm antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT stevensonwilliams antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity AT wardchristopherm antiglycoproteinvimediatedimmunethrombocytopeniaanunderrecognizedandsignificantentity |